Pharma Equity Group A/S (OCSE:PEG) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pharma Equity Group A/S's Free Cash Flow for the three months ended in Mar. 2024 was kr-7.83 Mil. Pharma Equity Group A/S's Revenue for the three months ended in Mar. 2024 was kr0.00 Mil. Therefore, Pharma Equity Group A/S's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Pharma Equity Group A/S's current FCF Yield % is -7.69%.

The historical rank and industry rank for Pharma Equity Group A/S's FCF Margin % or its related term are showing as below:

OCSE:PEG's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.2
* Ranked among companies with meaningful FCF Margin % only.

Pharma Equity Group A/S FCF Margin % Historical Data

The historical data trend for Pharma Equity Group A/S's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S FCF Margin % Chart

Pharma Equity Group A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Pharma Equity Group A/S Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Pharma Equity Group A/S's FCF Margin %

For the Biotechnology subindustry, Pharma Equity Group A/S's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Equity Group A/S's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's FCF Margin % falls into.

Pharma Equity Group A/S FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pharma Equity Group A/S's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-16.697	/	0
	=	%

Pharma Equity Group A/S's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-7.828	/	0
	=	%

Pharma Equity Group A/S FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Equity Group A/S (OCSE:PEG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970

Website

https://www.pharmaequitygroup.com

Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.